Fisher & Paykel Healthcare Corporation Limited (NZSX:FPH, ASX:FPH) will announce today at its investor day in Sydney the introduction of two innovative new products, the F&P Eson™ 2 nasal mask for the treatment of obstructive sleep apnea (OSA) and the F&P HumiGardTM SH870 System for the delivery of warm, humidified CO₂ during open and laparoscopic surgery.

F&P Eson™ 2 Nasal Mask
The F&P Eson 2 is the first of the next generation of Fisher & Paykel Healthcare’s comfortable and easy-to-use masks and builds on the success of the F&P Eson nasal mask with more than 20 design improvements.

“Our development team has focused on ease of use, to provide sleep professionals and patients confidence at every step from titration through to adherence” commented Lewis Gradon, Fisher & Paykel Healthcare’s Senior Vice President of Products and Technology and CEO Designate. “The F&P Eson has been our best performing nasal mask and has proven extremely popular with both healthcare providers and patients. We believe with the large number of design improvements the F&P Eson 2 will be even more popular” said Mr Gradon.

F&P Eson 2 retains the same patented RollFit™ Seal technology as F&P Eson. RollFit automatically adjusts to effectively fit a wide variety of faces and aims to maintain a seal while minimising the force applied to the bridge of the nose. The F&P Eson 2 includes intuitive headgear which has been completely redesigned for improved usability and fitting. VisiBlue™ highlights have been incorporated into key mask components to assist patients with mask orientation, use, and assembly. VisiBlue also assists providers to simplify instruction on equipment use and care.

“We put the patient and their needs at the centre of our mask design and, like all of our masks, the F&P Eson 2 is designed to seal comfortably, simplify use and improve treatment acceptability. Our innovative technologies have significantly advanced mask simplicity and performance, increasing the chance of long-term therapy success and, ultimately, improving patient care and outcomes” said Mr Gradon.

The F&P Eson 2 mask will initially be available in New Zealand and Australia from November, followed by Canada and Europe and then the United States on receipt of US FDA clearance.

F&P HumiGard™ SH870 Surgical Humidification System

Design of the F&P HumiGard™ SH870 Surgical Humidification System has focused on simplicity and usability for time-poor surgical staff. Auto detect software enables automatic detection of flow variations required for insufflation during open and laparoscopic surgery, while a preassembled tubing set significantly reduces setup time. Feedback from surgical staff has been critical in refining the delivery of this next generation technology enabling therapy adoption to be as seamless as possible.

“In recent years the focus of surgical humidification has been on its use during laparoscopic surgery, however mounting clinical evidence has demonstrated significant patient benefits such as improved perioperative hypothermia when utilised during open surgery. We believe that this new HumiGard system will facilitate accelerated growth in the uptake of surgical humidification by hospitals in a number of our key markets” concluded Mr Gradon.

The SH870 is being introduced into New Zealand, Australia, and the UK in November followed by multiple European markets in January.

The company's presentation to investors and analysts at its investor day in Sydney can be downloaded from www.fphcare.com/investor/presentations/.

About Fisher & Paykel Healthcare
Fisher & Paykel Healthcare is a leading designer, manufacturer and marketer of products and systems for use in respiratory care, acute care, surgery and the treatment of obstructive sleep apnea.  The company’s products are sold in over 120 countries worldwide. For more information about the company, visit our website www.fphcare.com.

Contact: Marcus Driller, Investor Relations & Corporate Affairs Manager on +64 9 574 0110.